0000899243-23-020714.txt : 20231229 0000899243-23-020714.hdr.sgml : 20231229 20231229203036 ACCESSION NUMBER: 0000899243-23-020714 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231227 FILED AS OF DATE: 20231229 DATE AS OF CHANGE: 20231229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Jonathan CENTRAL INDEX KEY: 0001779805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 231529190 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-27 0 0001744659 Akero Therapeutics, Inc. AKRO 0001779805 Young Jonathan C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Operating Officer 0 Common Stock 2023-12-27 4 M 0 5414 6.36 A 190545 D Common Stock 2023-12-27 4 S 0 5414 24.00 D 185131 D Common Stock 20000 I By EA Irrevocable Trust Common Stock 20000 I By CM Irrevocable Trust Common Stock 20000 I By JL Irrevocable Trust Stock Option (Right to Buy) 6.36 2023-12-27 4 M 0 5414 0.00 D 2029-01-15 Common Stock 5414 43064 D These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The options are vested and currently exercisable. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.0000 to $24.0003, inclusive. /s/ Jonathan Young 2023-12-29